Date:3/12/2010

3,535,755 8,066,023 --------- --------- --------- --------- Operating loss (5,425,032) (2,623,160) (13,535,755) (8,066,023) Derivative instrument (expense) income (270,959) 296,335 (8,567,917) 1,103,682 Interest income 1,850 20,317 73,833 299,956 Other expense (3,441) (202,500) (26,753) (202,500) Interest expense - - - - --------- --------- --------- --------- Net loss $(5,697,582) $(2,509,008) $(22,056,592) $(6,864,885) =========== =========== ============ =========== Common share data: Basic and diluted loss per share $(0.18) $(0.10) $(0.82) $(0.27) ====== ====== ====== ====== Weighted average number of basic and diluted shares outstanding 31,040,910 25,346,756 27,072,556 25,300,703

    
    
    Delcath Systems, Inc.                                                     
    Statement of Cash Flows as of December 31, 2009 and 2008      
                                                                              
                                                         2009         2008 
                                                         ----         ---- 
    Cash flows from operating activities:                                     
      Net loss                                      $(22,056,592) $(6,864,885)
      Adjustments to reconcile net loss to net                                
       cash used in operating activities:                                     
        Stock option compensation expense              1,578,673      379,546 
        Stock and warrant compensation expense           736,416      28
'/>"/>
SOURCE  Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference